BULLISHWHALES
BullishWhales · Analysts · Analyst Profile
BW Score Rank#127 of 347

Louise Chen

Cantor Fitzgerald · Equity Research Analyst
EstablishedRating since 2021No new ratings since Nov 2024

Analyst rating accuracy & track record

Louise Chen is an equity research analyst at Cantor Fitzgerald. Bullish Whales has scored 52 of their stock calls across 18 companies. Their picks beat their sector 43% of the time over the next 12 months, and their price targets were reached 21% of the time within a year.

Win % vs sector
43%
PT Hit % (12mo)
21%
Avg sector-excess
−3.2%
Scored calls
52
Tickers
18
Tier
Established

Track record

Bullish Whales has scored 52 of Louise Chen's stock calls across 18 companies, dating back to 2021. Their rated stocks beat their own sector 43% of the time over the next 12 months. On a typical call, a Chen pick returned −3.2% more than its sector over the following year.

Of the scored calls, 52 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
PCVXVaxcyte Inc
BuyNov 2024−59.0%
NVONovo Nordisk A/S
Buy$160.00Nov 2024−55.2%Miss
ZLABZai Lab Ltd
BuyOct 2024−19.2%
ZVRAZevra Therapeutics Inc.
BuyOct 2024+38.9%
NVONovo Nordisk A/S
Buy$160.00Oct 2024−45.3%Miss
ZVRAZevra Therapeutics Inc.
BuyOct 2024+36.9%
NVONovo Nordisk A/S
Buy$160.00Sep 2024−39.6%Miss
NVONovo Nordisk A/S
Buy$160.00Sep 2024−45.0%Miss
EOLSEvolus Inc
BuySep 2024−50.9%
NVONovo Nordisk A/S
Buy$160.00Sep 2024−47.5%Miss
IMVTImmunovant Inc
BuySep 2024−35.3%
EOLSEvolus Inc
BuySep 2024−41.8%
MESOMesoblast Ltd
BuyAug 2024+116.3%
LYRALyra Therapeutics Inc
BuyAug 2024−43.5%
ZVRAZevra Therapeutics Inc.
BuyAug 2024+35.6%
ZLABZai Lab Ltd
BuyAug 2024+109.7%
ZVRAZevra Therapeutics Inc.
BuyAug 2024+53.8%
INVAInnoviva Inc
BuyAug 2024+9.2%
INVAInnoviva Inc
BuyJul 2024+6.6%
ZLABZai Lab Ltd
BuyJul 2024+106.2%
ZLABZai Lab Ltd
BuyJun 2024+112.5%
PCVXVaxcyte Inc
BuyJun 2024−47.9%
LYRALyra Therapeutics Inc
BuyJun 2024−14.4%
INVAInnoviva Inc
BuyJun 2024+40.3%
MESOMesoblast Ltd
BuyJun 2024+57.2%
ANLAdlai Nortye Ltd. American Depositary Shares
BuyJun 2024−51.5%
ATOSAtossa Genetics Inc
BuyJun 2024−21.9%
AMRNAmarin Corporation PLC
BuyJun 2024−0.9%
INVAInnoviva Inc
BuyJun 2024+41.1%
AMRNAmarin Corporation PLC
BuyJun 2024+1.4%
MESOMesoblast Ltd
BuyJun 2024+64.5%
ATOSAtossa Genetics Inc
BuyMay 2024−25.5%
PCVXVaxcyte Inc
BuyMay 2024−46.1%
PDSBPDS Biotechnology Corp
BuyMay 2024−59.7%
SCYXScynexis Inc
BuyApr 2024−36.0%
ZVRAZevra Therapeutics Inc.
BuyApr 2024+42.1%
ANLAdlai Nortye Ltd. American Depositary Shares
Buy$30.00Oct 2023−96.2%Miss
ZLABZai Lab Ltd
Buy$70.00Oct 2023−14.1%Miss
MESOMesoblast Ltd
Buy$17.00Sep 2023+155.5%Miss
ZLABZai Lab Ltd
Buy$70.00Sep 2023−37.7%Miss
CNTBConnect Biopharma Holdings Ltd
Buy$5.00Sep 2023+24.0%Miss
ATOSAtossa Genetics Inc
Buy$5.00Sep 2023+38.9%Miss
HCMHUTCHMED DRC
Buy$50.00Sep 2023+0.8%Miss
MESOMesoblast Ltd
Buy$17.00Aug 2023+106.6%Miss
SCYXScynexis Inc
Buy$15.00Aug 2023−52.8%Miss
ZLABZai Lab Ltd
Buy$70.00Aug 2023−49.3%Miss
HCMHUTCHMED DRC
Buy$50.00Jul 2023+24.9%Miss
VYNEVyne Therapeutics Inc
Buy$9.00May 2023−73.6%Miss
MESOMesoblast Ltd
Buy$23.00Feb 2023−84.1%Miss
CNTBConnect Biopharma Holdings Ltd
Buy$5.00Jun 2022+51.9%Miss
Go to

Louise Chen: analyst track record FAQ

Is Louise Chen a good stock analyst?

Yes, by track record. Louise Chen ranks number 127 of 347 of the analysts Bullish Whales scores, with a BW Score of 40 out of 100. Past results do not guarantee future ones.

What is Louise Chen's win rate?

Louise Chen's win rate is 43%. Across 52 scored calls, their rated stocks beat their sector 43% of the time over the next 12 months. On a typical call they returned −3.2% more than the sector.

What stocks and sectors does Louise Chen cover?

Louise Chen covers 18 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Louise Chen's price targets accurate?

Louise Chen's price targets are reached within 12 months 21% of the time. The base rate across all analysts Bullish Whales tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Bullish Whales scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Louise Chen's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Bullish Whales score analyst accuracy?

Bullish Whales scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Louise Chen rank among Wall Street analysts?

Louise Chen ranks number 127 of 347 by BW Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.

v1.0.30